Innovate

Discover the latest innovations in computer-aided reasoning and information systems.

Discover how Vitic can assist with providing expert toxicity data for the ICH M7 guidelines on mutagenic impurities for an efficient workflow.

Driving efficient early-stage ICH M7 classification through reliable mutagenic and carcinogenic data

In this latest blog, we will define the difference between certainty and uncertainty in the ICH M7 guideline for mutagenic impurities. Delving into the power of existing experimental data, we’ll address how Vitic’s expert toxicity database can accelerate the workflow of Classes 1, 2 and 5 in mutagenicity risk assessments. To Toxicologists, the ICH M7 […]

Driving efficient early-stage ICH M7 classification through reliable mutagenic and carcinogenic data Read More »

KAptis Weight of Evidence ICH S1b(r1)

Applying ICH S1B(R1) in 5 steps: Carcinogenicity assessment made simple with Kaptis

Carcinogenicity assessment is a critical step in drug development. Teams must balance regulatory compliance, development timelines, and ethical testing, often with incomplete datasets. The revised ICH S1B(R1) guideline introduces a weight-of-evidence (WoE) approach that provides a more structured, efficient, and human-relevant path forward. By applying this framework, organisations can benefit from: $2 – 4M cost

Applying ICH S1B(R1) in 5 steps: Carcinogenicity assessment made simple with Kaptis Read More »

blog images

ICH M7 control option 4: How to confidently demonstrate control of mutagenic impurities in API synthesis (without analytical testing)

If you’re currently relying solely on analytical testing to check for mutagenic impurities in your active pharmaceutical ingredient (API), there is a more time- and cost-effective option available that doesn’t compromise patient safety. Recent data for a medium-sized pharmaceutical company showed that you could save $1.35M annually and reduce time taken by 77%, using in

ICH M7 control option 4: How to confidently demonstrate control of mutagenic impurities in API synthesis (without analytical testing) Read More »

Ready to discover the power of in silico chemical structure search using Vitic? Here's everything you need to know about toxicity database searching

The power of in silico structure searching to achieve data driven decision making with confidence

In this blog, we explore the value of chemical structure search functionality in Vitic. Structure searching directs our members toward toxicity insights that can help guide their risk and safety assessments. We’ll discuss how chemical structure searches are conducted and the value that a toxicity database like Vitic can bring to decision making. A key

The power of in silico structure searching to achieve data driven decision making with confidence Read More »

The evolving role of genotox assessments

Webinar recap: Industry and regulator perspectives on in silico genotoxicity assessment

In a recent Lhasa Limited webinar, experts from BfR (the German Federal Institute for Risk Assessment), Syngenta, and Lhasa came together to explore how in silico tools are being used to support genotoxicity assessments. The session delivered a thorough overview of how these advanced computational methods are applied in both regulatory and industry settings, focusing

Webinar recap: Industry and regulator perspectives on in silico genotoxicity assessment Read More »

Enhancing the Ames test for N-Nitrosamines: Key findings from a multi-sector study

Enhancing the Ames test for N-nitrosamines: Key findings from a multi-sector study

The ICH M7(R2) Guideline (2023) continues to recommend the bacterial reverse mutation assay (Ames test), conducted in accordance with OECD 471, as a primary tool for assessing the mutagenic potential of pharmaceutical impurities, including nitrosamines. While the Ames test is generally predictive of rodent carcinogenicity, concerns remain about its sensitivity under standard conditions, particularly when

Enhancing the Ames test for N-nitrosamines: Key findings from a multi-sector study Read More »

Understanding nitrosourea Acceptable Intake limits via read-across

Navigating the EMA guidelines: Understanding nitrosourea acceptable intake limits via read-across methods

In the ever-evolving landscape of pharmaceutical regulations, staying abreast of the latest guidelines is crucial for ensuring the safety and efficacy of drug products. Recently, the European Medicines Agency (EMA) updated its guidelines to include specific nitrosourea acceptable intake (AI) limits – a class of N-nitroso compounds known for their potential carcinogenicity. In our recent

Navigating the EMA guidelines: Understanding nitrosourea acceptable intake limits via read-across methods Read More »

Life at Lhasa video 1

Advancing drug discovery though data-driven federated learning

A new paper, “Data-driven federated learning in drug discovery with knowledge distillation”, was recently published in Nature Machine Intelligence, the leading journal for Machine Learning and AI. It explores the potential for federated learning to advance drug discovery through secure, collaborative research, representing a major step forward in privacy-preserving machine learning.   What is Federated

Advancing drug discovery though data-driven federated learning Read More »

Blog image for how to overcome challenges in forced degradation studies with Zeneth

How to overcome the critical challenges faced in forced degradation studies

At Lhasa we know that there are many challenges involved in carrying out risk assessments for drug substances and drug products, to ultimately ensure a safe and effective product for patients. Forced degradation studies are essential in pharmaceutical development to assess drug stability and ensure product quality and safety. These studies help identify degradation pathways,

How to overcome the critical challenges faced in forced degradation studies Read More »

Why prevalence shifts matter in machine learning

Why prevalence shifts matter in machine learning

In machine learning, the validation of binary classifiers, algorithms that categorise data into two classes, is essential. However, a frequently overlooked issue is prevalence shift, which occurs when two test datasets have different rates of positive instances. This phenomenon can distort performance metrics, leading to incorrect model evaluations. Understanding the problem Prevalence shift fundamentally affects

Why prevalence shifts matter in machine learning Read More »